Zevra Therapeutics, Inc. beat EPS estimates 44% of the time across 16 reported quarters (7 beats, 9 misses), averaging -19.4% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | not reported | $0.25 | not reported | not reported | Q2 FY26 call · transcript |
| Q1 FY26 | not reported | $0.18 | not reported | not reported | |
| Q4 FY25 | not reported | $1.16 | not reported | not reported | Q4 FY25 call · transcript |
| Q3 FY25 | not reported | $-0.01 | not reported | not reported | |
| Q2 FY25 | $-0.09 | $-0.06 | +33.3% | Beat | |
| Q1 FY25 | not reported | $-0.06 | not reported | not reported | |
| Q4 FY24 | $-0.39 | $-0.67 | -71.8% | Miss | |
| Q3 FY24 | $-0.44 | $-0.69 | -56.8% | Miss | |
| Q2 FY24 | $-0.47 | $-0.48 | -2.1% | Miss | |
| Q1 FY24 | $-0.49 | $-0.40 | +18.4% | Beat | |
| Q4 FY23 | $-0.20 | $-0.40 | -100.0% | Miss | |
| Q3 FY23 | $-0.29 | $-0.40 | -37.9% | Miss |
Back to ZVRA overview · ZVRA holders · ZVRA KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.